Epoetin (Epo) is physiologically present in the human body, stimulating erythropoiesis from bone marrow. Anemia is observed in cancer patients submitted to high-dose chemotherapy (HDCT), mainly caused by myelosuppression. Epoetin alfa has been widely used to treat the anemia that develops in the HDCT setting. Controlled studies in patients with hematologic malignancies or solid tumors who received Epo following HDCT have shown a decreased red blood cell transfusion requirement at least in patients receiving allogeneic bone marrow transplantation (BMT), while results in patients receiving autologous BMT have been disappointing. The administration of Epo before HDCT, in a period when bone marrow is still responsive to growth factors, may represent a new strategy aimed at decreasing the degree of anemia in these patients. A combination of granulocyte-colony stimulating factor and Epo has proved to be effective in mobilizing stem cell and committed myeloid/erythroid precursors.

[The use of erythropoietin alpha in programs of high-dose chemotherapy] / M., Danova; M., Aglietta; Pierelli, Luca; S., Ferrari; A., Perillo; G., Scambia; D., Henry. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 91:12(2000), pp. 681-689.

[The use of erythropoietin alpha in programs of high-dose chemotherapy].

PIERELLI, LUCA;
2000

Abstract

Epoetin (Epo) is physiologically present in the human body, stimulating erythropoiesis from bone marrow. Anemia is observed in cancer patients submitted to high-dose chemotherapy (HDCT), mainly caused by myelosuppression. Epoetin alfa has been widely used to treat the anemia that develops in the HDCT setting. Controlled studies in patients with hematologic malignancies or solid tumors who received Epo following HDCT have shown a decreased red blood cell transfusion requirement at least in patients receiving allogeneic bone marrow transplantation (BMT), while results in patients receiving autologous BMT have been disappointing. The administration of Epo before HDCT, in a period when bone marrow is still responsive to growth factors, may represent a new strategy aimed at decreasing the degree of anemia in these patients. A combination of granulocyte-colony stimulating factor and Epo has proved to be effective in mobilizing stem cell and committed myeloid/erythroid precursors.
2000
administration /&/ dosage/adverse effects; anemia; antineoplastic agents; blood transfusion; blood/therapeutic use; bone marrow; chemically induced/therapy; drug administration schedule; drug effects; erythropoietin; granulocyte colony-stimulating factor; granulocyte-macrophage colony-stimulating factor; hematopoietic stem cell mobilization; hematopoietic stem cells; hemoglobin a; humans; metabolism; methods; recombinant proteins; therapeutic use
01 Pubblicazione su rivista::01a Articolo in rivista
[The use of erythropoietin alpha in programs of high-dose chemotherapy] / M., Danova; M., Aglietta; Pierelli, Luca; S., Ferrari; A., Perillo; G., Scambia; D., Henry. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 91:12(2000), pp. 681-689.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/484156
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact